olaparib
Illumina, Merck Partner to Advance Homologous Recombination Deficiency CDx, Research Assay
Under the terms of the deal, Illumina will develop a new HRD CDx for the EU and UK markets and a research-use only HRD assay that will be add-on content for its TSO 500 panel.
Lynparza Benefit in Early BRCA-Mutated Breast Cancer Reignites Universal Genetic Testing Discussion
Premium
The OlympiA trial showed a disease-free survival benefit with adjuvant PARP inhibitor therapy for early-stage, BRCA1/2-mutated, HER2-negative breast cancer patients.
Uterine Leiomyosarcoma Sequences Point to Potentially Targetable Somatic Mutations
Using genome, exome, or transcriptome sequences from dozens of uterine leiomyosarcoma samples, researchers found alterations that may respond to existing targetable treatments.
Myriad Genetics Expands MyChoice CDx Access Through Partnerships in Europe, China
A deal with Burning Rock will allow the test to be used in trials and clinics in China, and Myriad will license its technology to French and German pathology labs.
FDA Approves Foundation Medicine Liquid Biopsy Test as CDx for Lynparza
The test will use a blood-based biopsy to detect patients with BRCA1, BRCA2, and/or ATM alterations in metastatic castration-resistant prostate cancer.